User menu

Dose tailoring of dabigatran etexilate: obvious or excessive?

Bibliographic reference Douxfils, Jonathan ; Mullier, François ; Dogné, Jean-Michel. Dose tailoring of dabigatran etexilate: obvious or excessive?. In: Expert Opinion on Drug Safety, Vol. 14, no. 8, p. 1283-1289 (2015)
Permanent URL
  1. Powell J. Robert, Are New Oral Anticoagulant Dosing Recommendations Optimal for All Patients?, 10.1001/jama.2015.59
  2. Lu Y., Branstad R., Karim R. M., Asinger R. W., Consideration of clinical variables for choosing new anticoagulant alternatives to warfarin for the management of non-valvular atrial fibrillation, 10.1111/jcpt.12207
  3. Legrand Matthieu, The Use of Dabigatran in Elderly Patients, 10.1001/archinternmed.2011.314
  4. McConeghy Kevin W., Bress Adam, Qato Dima M., Wing Coady, Nutescu Edith A., Evaluation of Dabigatran Bleeding Adverse Reaction Reports in the FDA Adverse Event Reporting System during the First Year of Approval, 10.1002/phar.1415
  5. Southworth Mary Ross, Reichman Marsha E., Unger Ellis F., Dabigatran and Postmarketing Reports of Bleeding, 10.1056/nejmp1302834
  6. Hernandez Inmaculada, Baik Seo Hyon, Piñera Antonio, Zhang Yuting, Risk of Bleeding With Dabigatran in Atrial Fibrillation, 10.1001/jamainternmed.2014.5398
  7. Lauffenburger J. C., Farley J. F., Gehi A. K., Rhoney D. H., Brookhart M. A., Fang G., Effectiveness and Safety of Dabigatran and Warfarin in Real-World US Patients With Non-Valvular Atrial Fibrillation: A Retrospective Cohort Study, 10.1161/jaha.115.001798
  8. Huisman Menno V., Lip Gregory Y.H., Diener Hans C., Dubner Sergio J., Halperin Jonathan L., Ma Chang S., Rothman Kenneth J., Teutsch Christine, Zint Kristina, Ackermann Diana, Clemens Andreas, Bartels Dorothee B., Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: A global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation, 10.1016/j.ahj.2013.12.006
  9. Kakkar Ajay K., Mueller Iris, Bassand Jean-Pierre, Fitzmaurice David A., Goldhaber Samuel Z., Goto Shinya, Haas Sylvia, Hacke Werner, Lip Gregory Y.H., Mantovani Lorenzo G., Verheugt Freek W.A., Jamal Waheed, Misselwitz Frank, Rushton-Smith Sophie, Turpie Alexander G.G., International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD), 10.1016/j.ahj.2011.09.011
  10. Piccini Jonathan P., Fraulo Elizabeth S., Ansell Jack E., Fonarow Gregg C., Gersh Bernard J., Go Alan S., Hylek Elaine M., Kowey Peter R., Mahaffey Kenneth W., Thomas Laine E., Kong Melissa H., Lopes Renato D., Mills Roger M., Peterson Eric D., Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF, 10.1016/j.ahj.2011.07.001
  11. Stangier Joachim, Clemens Andreas, Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, 10.1177/1076029609343004
  12. ten Cate Hugo, New oral anticoagulants: discussion on monitoring and adherence should start now!, 10.1186/1477-9560-11-8
  13. Reilly Paul A., Lehr Thorsten, Haertter Sebastian, Connolly Stuart J., Yusuf Salim, Eikelboom John W., Ezekowitz Michael D., Nehmiz Gerhard, Wang Susan, Wallentin Lars, The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients, 10.1016/j.jacc.2013.07.104
  14. Chan N. C., Coppens M., Hirsh J., Ginsberg J. S., Weitz J. I., Vanassche T., Douketis J. D., Schulman S., Eikelboom J. W., Real-world variability in dabigatran levels in patients with atrial fibrillation, 10.1111/jth.12823
  15. Pare G., Eriksson N., Lehr T., Connolly S., Eikelboom J., Ezekowitz M. D., Axelsson T., Haertter S., Oldgren J., Reilly P., Siegbahn A., Syvanen A.-C., Wadelius C., Wadelius M., Zimdahl-Gelling H., Yusuf S., Wallentin L., Genetic Determinants of Dabigatran Plasma Levels and Their Relation to Bleeding, 10.1161/circulationaha.112.001233
  16. Baglin T., Hillarp A., Tripodi A., Elalamy I., Buller H., Ageno W., Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 10.1111/jth.12149
  17. Baglin Trevor, Keeling David, Kitchen Steve, Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology, 10.1111/bjh.12052
  18. Douxfils J, Biomed Res Int (2014)
  19. Hapgood G., Butler J., Malan E., Chunilal S., Tran H., The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples : , 10.1160/th13-04-0301
  20. Douxfils J., Dogné J.-M., Mullier F., Chatelain B., Rönquist-Nii Y., Malmström R. E., Hjemdahl P., Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate : , 10.1160/th13-03-0202
  21. Douxfils J., Lessire S., Dincq A.-S., Hjemdahl P., Rönquist-Nii Y., Pohanka A., Gourdin M., Chatelain B., Dogné J.-M., Mullier F., Estimation of dabigatran plasma concentrations in the perioperative setting : An ex vivo study using dedicated coagulation assays, 10.1160/th14-09-0808
  22. Heidbuchel Hein, Verhamme Peter, Alings Marco, Antz Matthias, Hacke Werner, Oldgren Jonas, Sinnaeve Peter, Camm A. John, Kirchhof Paulus, European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, 10.1093/europace/eut083
  23. BOUNAMEAUX H., REBER G., New oral antithrombotics: a need for laboratory monitoring. Against, 10.1111/j.1538-7836.2010.03759.x
  24. MISMETTI P., LAPORTE S., New oral antithrombotics: a need for laboratory monitoring. For, 10.1111/j.1538-7836.2010.03764.x
  25. Rao Rama B., Regarding the Effect of Dabigatran Plasma Concentrations, 10.1016/j.jacc.2014.02.610
  26. Douxfils J., Chatelain B., Dogné J.-M., Mullier F., Real-world variability in dabigatran levels in patients with atrial fibrillation: comment, 10.1111/jth.12880
  27. Ruff Christian T, Giugliano Robert P, Braunwald Eugene, Morrow David A, Murphy Sabina A, Kuder Julia F, Deenadayalu Naveen, Jarolim Petr, Betcher Joshua, Shi Minggao, Brown Karen, Patel Indravadan, Mercuri Michele, Antman Elliott M, Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial, 10.1016/s0140-6736(14)61943-7